Effectiveness of antihyperlipidemic drug management in clinical practice

Clinical Therapeutics

Volumn 21, Issue 11, 1999, Pages 1973-1987

  Andrade, Susan E ^a,e   Saperia, Gordon M ^b   Berger, Marc L ^c   Platt, Richard ^d  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b Fallon Clinic   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Antihyperlipidemic drugs; Coronary heart disease; Hospitalization; Lipids

Indexed keywords

ANTILIPEMIC AGENT; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DEXTROTHYROXINE; GEMFIBROZIL; MEVINOLIN; NICOTINIC ACID; PROBUCOL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DATA BASE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION;

EID: 0032796433     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)86743-0     Document Type: Note

References (25)

1. 1. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
2. 2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
3. 3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
4. 4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
5. 5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
6. 6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air ForceHexas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
7. 7. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-1131.
8. 8. Andrade SE, Platt R, Gottlieb LK, et al. Discontinuations of antihyperlipidemic drug therapy: Assessment by means of automated databases. Pharmacoepidemiol Drug Saf. 1996;5:113-120.
9. 9. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA. 1998; 279:1458-1462.
10. 10. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996; 164:208-211.
11. 11. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
12. 12. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988; 148:36-69.
13. 13. International Classification of Diseases, Ninth Revision. New York, NY: McGraw-Hill; 1995:3-305.
14. 14. O'Connor PJ, Rush WA, Trence DL. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization. J Fam Pract. 1997;44:462-467.
15. 15. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
16. 16. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
17. 17. Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol. 1997;30:325-333.
18. 18. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endotheliumdependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
19. 19. O'Driscoll G, Green K, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.
20. 20. Treasure CB, Klein L, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
21. 21. Weber C, Erl W, Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CDIIb expression and CDIIb-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997; 30:1212-1217.
22. 22. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996;78:409-414.
23. 23. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336:332-336.
24. 24. Kinosian BP, Eisenberg JM. Cutting into cholesterol: Cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988;259:2249-2254.
25. 25. Weinstein M, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health. 1985;6:41-63.